Position in GUTS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$163,902
-$136,547 QoQ
Shares Held
357,865
+162.0% QoQ
Ownership
0.226%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in GUTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Shay Capital LLC holds $54,653,360 across 39 Biotechnology names. GUTS ranks #30 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | QNCX |
Quince Therapeutics, Inc.
|
1,772,909 | $35,812,761 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
16,500 | $1,388,805 | |
| 3 | SRRK |
Scholar Rock Holding Corp
|
28,000 | $1,376,480 | |
| 4 | BCAX |
Bicara Therapeutics Inc.
|
63,500 | $1,263,015 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
12,000 | $1,167,000 | |
| 6 | MANE |
Veradermics, Inc
|
18,000 | $1,136,700 | |
| 7 | QURE |
uniQure N.V.
|
67,527 | $1,104,066 | |
| 8 | VYNE |
VYNE Therapeutics Inc.
|
1,610,242 | $962,924 |
All Filings in GUTS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $163,902 | 357,865 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $300,449 | 136,568 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $453,471 | 285,202 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||